Prescription Medicines
Rablon SR Tab. 50mg
- Product Category
- Overactive bladder treatment
- Active Ingredients
- Mirabegron
- Appearance
- Yellow, oval, film-coated extended-release tablets
- Reimbursement Code
- 648104630
01 / 02
1. Ingredient content
1 tablet
- Active ingredients:
Mirabegron (in-house specification) ----- 50.0mg
- Additives (tar colorant): Blue No. 2, Yellow No. 4, Yellow No. 5
- Other additives: butylhydroxytoluene, polyethylene oxide, magnesium stearate, sodium chloride, Opadry AMBII yellow (88A620026), colloidal silicon oxide, hydroxypropyl cellulose
2. Effectiveness
Adults: Treatment of symptoms of urinary urgency, frequency, and/or urge incontinence that may occur in patients with overactive bladder.
3. Dosage and dosage
In adults (including elderly patients), the recommended dose is 50 mg orally once a day.
This medicine can be administered with or without food. It should be swallowed with water and should not be chewed or crushed.
The following is a table of recommended daily doses with or without strong CYP3A inhibitors for patients with renal and hepatic impairment (see ‘Precautions for Use 5) Interactions’.
- Refer to the manual -
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to the main ingredient or other ingredients of this drug
2) Patients with severe uncontrolled hypertension (systolic blood pressure≥180mmHg and/or diastolic blood pressure≥110mmHg)
3) Patients with serious heart disease (symptoms may worsen as cases of increased blood pressure have been reported)
2. Administer with caution to the following patients.
1) Patients with congenital or acquired QT prolongation’ (see ‘4) General precautions’)
At therapeutic doses, this drug has not been shown to be clinically associated with QT prolongation in clinical trials. However, since the clinical trial did not include patients with a history of QT prolongation or taking medications that may prolong QT, the effect of this drug on these patients is unknown, and therefore caution should be exercised when administering this drug.
2) This drug has not been studied in the following patient groups, so administration is not recommended.
- Patients with end-stage renal disease (GFR<15mL/min/1.73m2 or patients requiring hemodialysis)
- Patients with severe hepatic impairment (Child-Pugh class C)
3) Because this drug interacts with enzyme inhibitors, administration is not recommended for the following patient groups.
- Patients with severe renal impairment who are taking a strong CYP3A4 inhibitor concomitantly (CFR 15-29mL/min/1.73m2)
- Patients with moderate hepatic impairment who are taking a strong CYP3A4 inhibitor concomitantly (Child-Pugh class B)
4) Patients with bladder outlet obstruction and patients taking antimuscarinic drugs to treat overactive bladder (see ‘4. General Precautions’)
5) This drug contains Yellow No. 4 (tartrazine) and Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to these ingredients or have a history of allergy.
3. Adverse reactions
1) Adverse reactions reported in foreign clinical trials
8,433 patients with overactive bladder received this drug in clinical trials. Of these, 5,648 patients took this drug at least once in the phase 2/3 clinical trial, and 622 patients took this drug for at least 1 year (365 days). In three 12-week, phase 3, double-blind, placebo-controlled trials, 88% of patients completed treatment and 4% of patients discontinued due to adverse events. Most adverse reactions were mild to moderate in severity.
During three 12-week Phase 3, double-blind, placebo-controlled trials, the most common adverse reactions reported in patients receiving 50 mg of ZELJANZ were tachycardia (1.2%) and urinary tract infection (2.9%). Tachycardia led to discontinuation of treatment in 0.1% of patients receiving 50 mg of this drug. Urinary tract infection did not cause treatment discontinuation in patients receiving 50 mg of this drug. Serious adverse events included atrial fibrillation (0.2%).
Adverse events observed in the 1-year (long-term) active comparator (muscarinic antagonist) controlled trial were similar in type and severity to those observed in the three 12-week phase 3 double-blind, placebo-controlled trials.
The table below presents adverse reactions observed in three 12-week phase 3 double-blind, placebo-controlled clinical trials.
[Table 1] Adverse reactions observed in three 12-week phase 3 double-blind, placebo-controlled trials - see instructions -
2) Adverse reactions reported in Asian clinical trials
1,103 Asian patients with overactive bladder received this drug in clinical trials.
During this 12-week, phase 3, multicenter, randomized, double-blind, placebo- and active-control, parallel-group study, the most common treatment-related adverse reaction (frequency ≥ 2.0%) reported in Asian patients receiving 50 mg of SERVANT was dry mouth (4.1%). The incidence of dry mouth in the 50 mg of this drug group was similar to that in the placebo group (4.4%). However, compared to the active comparator group (8.1%), the incidence of dry mouth was lower in the 50 mg group of patients, which is consistent with the pharmacological effect of antimuscarinic drugs.
The table below presents the most common treatment-related adverse events (frequency ≥2.0%) observed in this 12-week, phase 3, multicenter, randomized, double-blind, placebo- and active-drug-controlled, parallel-group trial.
[Table 2] Most common treatment-related adverse reactions (frequency ≥ 2.0%) observed in the 12-week, phase 3, multicenter, randomized, double-blind, placebo- and active-drug-controlled, parallel-group trial - see description -
3) Adverse reactions reported in foreign post-marketing experience
Because the following adverse reactions were voluntarily reported after marketing around the world, the frequency of these adverse reactions and their causal relationship with this drug have not been clearly established.
· Kidney and urinary system: urinary retention
· Digestive system: nausea, constipation, diarrhea
· Skin and subcutaneous tissue: angioedema
· Mental system: insomnia, confusion
· Nervous system: dizziness, headache
4) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,145 people over 6 years for re-examination in Korea, adverse events were reported in 5.18% (163/3, 145 people, 185 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual
4. General precautions
1) At doses of 50 mg or 100 mg, there was no effect on the QT interval individually adjusted for heart rate (QTcI interval) when evaluated by gender or in the overall group. However, it should be prescribed with caution in patients with a known history of QT prolongation or in patients taking medications known to prolong the QT interval.
The Thorough QT (TQT) study (164 healthy male volunteers and 153 healthy female volunteers with a mean age of 33 years) evaluated the effect on the QTcI interval of repeated doses of 50 mg (therapeutic dose), 100 mg, and 200 mg (supratherapeutic dose) once daily. Moxifloxacin 400 mg was used as an active control drug.
The upper limit of the one-sided 95% confidence interval did not exceed 10 msec at any time point in both men and women receiving the 50 mg and 100 mg doses. The mean difference from placebo for QTcI interval 5 hours after dosing in women receiving the 50-mg dose of ZELJANZ was 3.67 msec (one-sided 95% CI upper limit 5.72 msec). In men, the difference was 2.89 msec (one-sided 95% CI upper limit 4.90 msec). At the 200 mg dose, the QTcI interval did not exceed 10 msec at any time in men, whereas in women the upper limit of the one-sided 95% CI exceeded 10 msec between 0.5 and 6 hours, with the greatest difference from placebo at 5 hours, when the mean effect was 10.42 msec (one-sided upper 95% CI 13.44 msec). The results of QTcF and QTcIf were consistent with QTcI.
In this TQT trial, there was a dose-dependent increase in heart rate on ECG at doses ranging from 50 mg to 200 mg. In healthy subjects, the maximum mean difference from placebo ranged from 6.7 bpm at 50 mg to 17.3 bpm at 200 mg.
2) This drug may increase blood pressure. Patients taking this drug (especially those with high blood pressure) should have their baseline and periodic blood pressure measured.
3) In patients with overactive bladder (average age: 59 years) who received 50 mg of this drug once daily across three 12-week phase 3 double-blind, placebo-controlled trials, an increase in the mean difference from placebo of approximately 1 bpm in pulse rate and 1 mmHg or less in systolic/diastolic blood pressure (SBP/DBP) was observed. Changes in pulse rate and blood pressure are restored upon discontinuation of administration.
4) This drug has limited research data on patients with stage 2 hypertension (systolic pressure ≥160mmHg or diastolic pressure ≥100mmHg).
5) According to post-marketing experience with patients receiving this drug, urinary retention has been reported in patients with bladder outlet obstruction and patients taking antimuscarinic agents for the treatment of overactive bladder. Although controlled safety evaluation clinical trials in patients with bladder outlet obstruction have not demonstrated increased urinary retention in patients receiving this drug, caution should be exercised when administering this drug to patients with clinically significant bladder outlet obstruction. Additionally, caution should be exercised when administering this drug to patients taking antimuscarinics for the treatment of overactive bladder.
6) This drug has no or negligible effect on the ability to drive or operate machinery.
5. Interaction
1) As a result of in vitro tests, this drug is a substrate of CYP3A4, CYP2D6, butyrylcholinesterase, uridine diphosphate-glucuronosyltransferase (UGT), efflux transporter P-glycoprotein (P-gp), and influx organic cation transporter (OCT) OCT1, OCT2, and OCT3.
2) As a result of in vivo testing, clinically relevant drug interactions between this drug and other drugs that inhibit or induce one of the CYP isoenzymes or transporters or are substrates thereof are not expected, except for the inhibitory effect of this drug on the metabolism of CYP2D6 substrates.
3) Genetic polymorphisms of CYP2D6 have minimal effect on the mean plasma exposure of this drug. Therefore, no dosage adjustment of this drug is necessary when administered with CYP2D6 inhibitors or when administered to patients with reduced CYP2D6 metabolism.
4) In healthy volunteers, exposure (AUC) of this drug increases 1.8-fold in the presence of ketoconazole, a strong inhibitor of CYP3A and P-gp. No dose adjustment is necessary when this drug is co-administered with inhibitors of CYP3A or P-gp. However, the recommended dose for patients with mild or moderate renal impairment (GFR 30∼89 mL/min/1.73 m2) or mild hepatic impairment (Child-Pugh Class A) who are taking strong CYP3A inhibitors such as itraconazole, ketoconazole, ritonavir, and clarithromycin concomitantly is 25 mg once daily, regardless of meal. This drug is not recommended for patients with severe renal impairment (GFR 15-29 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh Class B) who are taking a strong CYP3A inhibitor concomitantly.
5) Substrates that induce CYP3A4 and P-gp reduce the plasma concentration of this drug. However, when rifampicin or other CYP3A4 and P-gp inducers are administered at subtherapeutic doses, no dose adjustment of this drug is necessary.
6) In healthy volunteers, the inhibition of CYP2D6 is moderate. Caution should be exercised when coadministering with drugs that have a narrow therapeutic window and are significantly metabolized by CYP2D6, such as thioridazine, type 1C antiarrhythmic drugs (e.g. flecainide, propafenone), and tricyclic antidepressants (e.g. imipramine). Additionally, caution should be exercised when coadministered with CYP2D6 substrates whose dosages are titrated individually.
7) This drug is a weak inhibitor of P-gp. Patients starting combination therapy with this drug and digoxin should initially be prescribed the lowest dose of digoxin, and serum digoxin concentrations should be monitored to titrate the digoxin dose to achieve the desired clinical effect. When co-administering this drug with sensitive P-gp substrates such as dabigatran, the inhibitory ability of this drug on P-gp must be taken into consideration.
8) No clinically relevant drug interactions were observed when this drug was co-administered at therapeutic doses with solifenacin, tamsulosin, warfarin, metformin, or combined oral contraceptives containing ethinyl estradiol and levonorgestrel. Therefore, dose adjustment is not necessary.
9) Increased exposure to this drug due to drug interactions may be associated with increased pulse rate.
6. Administration to pregnant women, lactating women, and children
1) Pregnant women
There is limited data on the use of this drug in pregnant women. Animal tests showed reproductive toxicity (see Section 9. Other 2)). Therefore, this drug is not recommended for use in pregnant women or women of childbearing potential who are not using contraception.
2) Administration to nursing mothers
It is not known whether this drug is excreted in human breast milk. This drug has been reported to be secreted into milk in rats, so it is not administered to nursing mothers.
3) Administration to children
The safety and effectiveness of this drug in children under 19 years of age have not yet been established.
7. Treatment in case of overdose
When a single 400 mg dose was administered to healthy volunteers, palpitations (1 out of 6 subjects) and increased pulse rates exceeding 100 beats per minute (3 out of 6 subjects) were reported. Repeated administration of up to 300 mg of this drug daily for 10 days in healthy volunteers resulted in increases in pulse rate and systolic blood pressure. Treatment for overdose should be symptomatic and supportive. Pulse rate, blood pressure, and ECG monitoring are recommended if overdose occurs.
8. Storage and handling precautions
1) Be careful to keep it out of reach of children.
2) Be careful not to replace it in another container as it may cause an accident or is undesirable in terms of maintaining quality.
9. Pharmaceutical equivalence test information
A. fasting test
The test drug Betagron extended-release tablets 50 mg (Mirabegron) [Genuone Science Co., Ltd.] and the reference drug Betamiga extended-release tablets 50 mg (Mirabegron) [Korea Astellas Pharmaceuticals Co., Ltd.] were orally administered to healthy adults, one tablet each, on an empty stomach in a 2 The coefficient of variation was 50%. When the comparative evaluation item value (AUCt) is log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference is within log 0.8 to log 1.25. When the comparative evaluation item value (Cmax) is log-transformed and statistically processed, the mean difference is within log 0.8 to log 1.25, and the 90% confidence interval of the log-transformed mean difference of Cmax corresponding to the coefficient of variation of 50% is log. Since it is within log 1.4319 of 0.6984, it has been proven to be biologically equivalent in accordance with Article 17 (4) of the Pharmaceutical Equivalence Test Standards.
* Table: refer to manual
B. Postprandial test
The test drug Betagron extended-release tablets 50 mg (Mirabegron) [Genuone Science Co., Ltd.] and the reference drug Betamiga extended-release tablets 50 mg (Mirabegron) [Korea Astellas Pharmaceuticals Co., Ltd.] were administered orally to healthy adults, one tablet each, on an empty stomach in a 2 The coefficient of variation was 37%. When the comparative evaluation item value (AUCt) is log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference is within log 0.8 to log 1.25, and when the comparative evaluation item value (Cmax) is log-transformed and statistically processed, the mean difference is within log 0.8 to log 1.25, and the 90% confidence interval of the log-transformed mean difference of Cmax, which corresponds to a coefficient of variation of 37%, is log. Since it is within log 1.3129 of 0.7617, it has been proven to be biologically equivalent in accordance with Article 17 (4) of the Pharmaceutical Equivalence Test Standards.
* Table: refer to manual
※ This drug uses the same raw materials as Genuine Science Co., Ltd. Betagron extended-release tablet 50 mg (Mirabegron) and the entire process was manufactured by Genuine Science Co., Ltd. using the same manufacturing method.
10. Other
1) The target organs of toxicity were identified in non-clinical tests, which are consistent with clinical observations. Transient elevations in liver enzymes and hepatocellular changes (necrosis and reduction of glycogen particles) were observed in rats. Increased heart rate has been observed in rats, rabbits, dogs, and monkeys. In vivo genotoxicity and carcinogenicity tests showed no genotoxic or carcinogenic potential.
2) The effect on fertility was not shown at sub-lethal doses (the human equivalent dose is 19 times higher than the MHRD (maximum recommended human dose)). Key observations in the rabbit fetal development study included cardiac malformations (aortic dilatation, cardiac hypertrophy) at systemic exposures 36 times higher than those observed in MHRD. Additionally, lung deformities (absence of parapulmonary lobes) and postimplantation miscarriage were observed in rabbits at a whole-body exposure 14 times higher than during MHRD observation, and reversible effects on ossification (ripple ribs, delayed ossification, ossified sternal iliac bones, and reduction in the number of metatarsals) were reported at a whole-body exposure 22 times higher than during MHRD observation. Observed embryo-fetal toxicity occurred at doses associated with maternal toxicity. The cardiac malformations observed in rabbits appear to be mediated through activation of beta 1 adrenergic receptors.
3) In a pharmacokinetic study conducted with this radioactively labeled drug, the parent compound and/or its metabolites were secreted into rat milk at a concentration 1.7 times higher than the plasma concentration 4 hours after administration.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
90 tablets/box (10 tablets/PTP×9)
7. Period of use
18 months from date of manufacture
1 tablet
- Active ingredients:
Mirabegron (in-house specification) ----- 50.0mg
- Additives (tar colorant): Blue No. 2, Yellow No. 4, Yellow No. 5
- Other additives: butylhydroxytoluene, polyethylene oxide, magnesium stearate, sodium chloride, Opadry AMBII yellow (88A620026), colloidal silicon oxide, hydroxypropyl cellulose
2. Effectiveness
Adults: Treatment of symptoms of urinary urgency, frequency, and/or urge incontinence that may occur in patients with overactive bladder.
3. Dosage and dosage
In adults (including elderly patients), the recommended dose is 50 mg orally once a day.
This medicine can be administered with or without food. It should be swallowed with water and should not be chewed or crushed.
The following is a table of recommended daily doses with or without strong CYP3A inhibitors for patients with renal and hepatic impairment (see ‘Precautions for Use 5) Interactions’.
- Refer to the manual -
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to the main ingredient or other ingredients of this drug
2) Patients with severe uncontrolled hypertension (systolic blood pressure≥180mmHg and/or diastolic blood pressure≥110mmHg)
3) Patients with serious heart disease (symptoms may worsen as cases of increased blood pressure have been reported)
2. Administer with caution to the following patients.
1) Patients with congenital or acquired QT prolongation’ (see ‘4) General precautions’)
At therapeutic doses, this drug has not been shown to be clinically associated with QT prolongation in clinical trials. However, since the clinical trial did not include patients with a history of QT prolongation or taking medications that may prolong QT, the effect of this drug on these patients is unknown, and therefore caution should be exercised when administering this drug.
2) This drug has not been studied in the following patient groups, so administration is not recommended.
- Patients with end-stage renal disease (GFR<15mL/min/1.73m2 or patients requiring hemodialysis)
- Patients with severe hepatic impairment (Child-Pugh class C)
3) Because this drug interacts with enzyme inhibitors, administration is not recommended for the following patient groups.
- Patients with severe renal impairment who are taking a strong CYP3A4 inhibitor concomitantly (CFR 15-29mL/min/1.73m2)
- Patients with moderate hepatic impairment who are taking a strong CYP3A4 inhibitor concomitantly (Child-Pugh class B)
4) Patients with bladder outlet obstruction and patients taking antimuscarinic drugs to treat overactive bladder (see ‘4. General Precautions’)
5) This drug contains Yellow No. 4 (tartrazine) and Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to these ingredients or have a history of allergy.
3. Adverse reactions
1) Adverse reactions reported in foreign clinical trials
8,433 patients with overactive bladder received this drug in clinical trials. Of these, 5,648 patients took this drug at least once in the phase 2/3 clinical trial, and 622 patients took this drug for at least 1 year (365 days). In three 12-week, phase 3, double-blind, placebo-controlled trials, 88% of patients completed treatment and 4% of patients discontinued due to adverse events. Most adverse reactions were mild to moderate in severity.
During three 12-week Phase 3, double-blind, placebo-controlled trials, the most common adverse reactions reported in patients receiving 50 mg of ZELJANZ were tachycardia (1.2%) and urinary tract infection (2.9%). Tachycardia led to discontinuation of treatment in 0.1% of patients receiving 50 mg of this drug. Urinary tract infection did not cause treatment discontinuation in patients receiving 50 mg of this drug. Serious adverse events included atrial fibrillation (0.2%).
Adverse events observed in the 1-year (long-term) active comparator (muscarinic antagonist) controlled trial were similar in type and severity to those observed in the three 12-week phase 3 double-blind, placebo-controlled trials.
The table below presents adverse reactions observed in three 12-week phase 3 double-blind, placebo-controlled clinical trials.
[Table 1] Adverse reactions observed in three 12-week phase 3 double-blind, placebo-controlled trials - see instructions -
2) Adverse reactions reported in Asian clinical trials
1,103 Asian patients with overactive bladder received this drug in clinical trials.
During this 12-week, phase 3, multicenter, randomized, double-blind, placebo- and active-control, parallel-group study, the most common treatment-related adverse reaction (frequency ≥ 2.0%) reported in Asian patients receiving 50 mg of SERVANT was dry mouth (4.1%). The incidence of dry mouth in the 50 mg of this drug group was similar to that in the placebo group (4.4%). However, compared to the active comparator group (8.1%), the incidence of dry mouth was lower in the 50 mg group of patients, which is consistent with the pharmacological effect of antimuscarinic drugs.
The table below presents the most common treatment-related adverse events (frequency ≥2.0%) observed in this 12-week, phase 3, multicenter, randomized, double-blind, placebo- and active-drug-controlled, parallel-group trial.
[Table 2] Most common treatment-related adverse reactions (frequency ≥ 2.0%) observed in the 12-week, phase 3, multicenter, randomized, double-blind, placebo- and active-drug-controlled, parallel-group trial - see description -
3) Adverse reactions reported in foreign post-marketing experience
Because the following adverse reactions were voluntarily reported after marketing around the world, the frequency of these adverse reactions and their causal relationship with this drug have not been clearly established.
· Kidney and urinary system: urinary retention
· Digestive system: nausea, constipation, diarrhea
· Skin and subcutaneous tissue: angioedema
· Mental system: insomnia, confusion
· Nervous system: dizziness, headache
4) Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 3,145 people over 6 years for re-examination in Korea, adverse events were reported in 5.18% (163/3, 145 people, 185 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual
4. General precautions
1) At doses of 50 mg or 100 mg, there was no effect on the QT interval individually adjusted for heart rate (QTcI interval) when evaluated by gender or in the overall group. However, it should be prescribed with caution in patients with a known history of QT prolongation or in patients taking medications known to prolong the QT interval.
The Thorough QT (TQT) study (164 healthy male volunteers and 153 healthy female volunteers with a mean age of 33 years) evaluated the effect on the QTcI interval of repeated doses of 50 mg (therapeutic dose), 100 mg, and 200 mg (supratherapeutic dose) once daily. Moxifloxacin 400 mg was used as an active control drug.
The upper limit of the one-sided 95% confidence interval did not exceed 10 msec at any time point in both men and women receiving the 50 mg and 100 mg doses. The mean difference from placebo for QTcI interval 5 hours after dosing in women receiving the 50-mg dose of ZELJANZ was 3.67 msec (one-sided 95% CI upper limit 5.72 msec). In men, the difference was 2.89 msec (one-sided 95% CI upper limit 4.90 msec). At the 200 mg dose, the QTcI interval did not exceed 10 msec at any time in men, whereas in women the upper limit of the one-sided 95% CI exceeded 10 msec between 0.5 and 6 hours, with the greatest difference from placebo at 5 hours, when the mean effect was 10.42 msec (one-sided upper 95% CI 13.44 msec). The results of QTcF and QTcIf were consistent with QTcI.
In this TQT trial, there was a dose-dependent increase in heart rate on ECG at doses ranging from 50 mg to 200 mg. In healthy subjects, the maximum mean difference from placebo ranged from 6.7 bpm at 50 mg to 17.3 bpm at 200 mg.
2) This drug may increase blood pressure. Patients taking this drug (especially those with high blood pressure) should have their baseline and periodic blood pressure measured.
3) In patients with overactive bladder (average age: 59 years) who received 50 mg of this drug once daily across three 12-week phase 3 double-blind, placebo-controlled trials, an increase in the mean difference from placebo of approximately 1 bpm in pulse rate and 1 mmHg or less in systolic/diastolic blood pressure (SBP/DBP) was observed. Changes in pulse rate and blood pressure are restored upon discontinuation of administration.
4) This drug has limited research data on patients with stage 2 hypertension (systolic pressure ≥160mmHg or diastolic pressure ≥100mmHg).
5) According to post-marketing experience with patients receiving this drug, urinary retention has been reported in patients with bladder outlet obstruction and patients taking antimuscarinic agents for the treatment of overactive bladder. Although controlled safety evaluation clinical trials in patients with bladder outlet obstruction have not demonstrated increased urinary retention in patients receiving this drug, caution should be exercised when administering this drug to patients with clinically significant bladder outlet obstruction. Additionally, caution should be exercised when administering this drug to patients taking antimuscarinics for the treatment of overactive bladder.
6) This drug has no or negligible effect on the ability to drive or operate machinery.
5. Interaction
1) As a result of in vitro tests, this drug is a substrate of CYP3A4, CYP2D6, butyrylcholinesterase, uridine diphosphate-glucuronosyltransferase (UGT), efflux transporter P-glycoprotein (P-gp), and influx organic cation transporter (OCT) OCT1, OCT2, and OCT3.
2) As a result of in vivo testing, clinically relevant drug interactions between this drug and other drugs that inhibit or induce one of the CYP isoenzymes or transporters or are substrates thereof are not expected, except for the inhibitory effect of this drug on the metabolism of CYP2D6 substrates.
3) Genetic polymorphisms of CYP2D6 have minimal effect on the mean plasma exposure of this drug. Therefore, no dosage adjustment of this drug is necessary when administered with CYP2D6 inhibitors or when administered to patients with reduced CYP2D6 metabolism.
4) In healthy volunteers, exposure (AUC) of this drug increases 1.8-fold in the presence of ketoconazole, a strong inhibitor of CYP3A and P-gp. No dose adjustment is necessary when this drug is co-administered with inhibitors of CYP3A or P-gp. However, the recommended dose for patients with mild or moderate renal impairment (GFR 30∼89 mL/min/1.73 m2) or mild hepatic impairment (Child-Pugh Class A) who are taking strong CYP3A inhibitors such as itraconazole, ketoconazole, ritonavir, and clarithromycin concomitantly is 25 mg once daily, regardless of meal. This drug is not recommended for patients with severe renal impairment (GFR 15-29 mL/min/1.73 m2) or moderate hepatic impairment (Child-Pugh Class B) who are taking a strong CYP3A inhibitor concomitantly.
5) Substrates that induce CYP3A4 and P-gp reduce the plasma concentration of this drug. However, when rifampicin or other CYP3A4 and P-gp inducers are administered at subtherapeutic doses, no dose adjustment of this drug is necessary.
6) In healthy volunteers, the inhibition of CYP2D6 is moderate. Caution should be exercised when coadministering with drugs that have a narrow therapeutic window and are significantly metabolized by CYP2D6, such as thioridazine, type 1C antiarrhythmic drugs (e.g. flecainide, propafenone), and tricyclic antidepressants (e.g. imipramine). Additionally, caution should be exercised when coadministered with CYP2D6 substrates whose dosages are titrated individually.
7) This drug is a weak inhibitor of P-gp. Patients starting combination therapy with this drug and digoxin should initially be prescribed the lowest dose of digoxin, and serum digoxin concentrations should be monitored to titrate the digoxin dose to achieve the desired clinical effect. When co-administering this drug with sensitive P-gp substrates such as dabigatran, the inhibitory ability of this drug on P-gp must be taken into consideration.
8) No clinically relevant drug interactions were observed when this drug was co-administered at therapeutic doses with solifenacin, tamsulosin, warfarin, metformin, or combined oral contraceptives containing ethinyl estradiol and levonorgestrel. Therefore, dose adjustment is not necessary.
9) Increased exposure to this drug due to drug interactions may be associated with increased pulse rate.
6. Administration to pregnant women, lactating women, and children
1) Pregnant women
There is limited data on the use of this drug in pregnant women. Animal tests showed reproductive toxicity (see Section 9. Other 2)). Therefore, this drug is not recommended for use in pregnant women or women of childbearing potential who are not using contraception.
2) Administration to nursing mothers
It is not known whether this drug is excreted in human breast milk. This drug has been reported to be secreted into milk in rats, so it is not administered to nursing mothers.
3) Administration to children
The safety and effectiveness of this drug in children under 19 years of age have not yet been established.
7. Treatment in case of overdose
When a single 400 mg dose was administered to healthy volunteers, palpitations (1 out of 6 subjects) and increased pulse rates exceeding 100 beats per minute (3 out of 6 subjects) were reported. Repeated administration of up to 300 mg of this drug daily for 10 days in healthy volunteers resulted in increases in pulse rate and systolic blood pressure. Treatment for overdose should be symptomatic and supportive. Pulse rate, blood pressure, and ECG monitoring are recommended if overdose occurs.
8. Storage and handling precautions
1) Be careful to keep it out of reach of children.
2) Be careful not to replace it in another container as it may cause an accident or is undesirable in terms of maintaining quality.
9. Pharmaceutical equivalence test information
A. fasting test
The test drug Betagron extended-release tablets 50 mg (Mirabegron) [Genuone Science Co., Ltd.] and the reference drug Betamiga extended-release tablets 50 mg (Mirabegron) [Korea Astellas Pharmaceuticals Co., Ltd.] were orally administered to healthy adults, one tablet each, on an empty stomach in a 2 The coefficient of variation was 50%. When the comparative evaluation item value (AUCt) is log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference is within log 0.8 to log 1.25. When the comparative evaluation item value (Cmax) is log-transformed and statistically processed, the mean difference is within log 0.8 to log 1.25, and the 90% confidence interval of the log-transformed mean difference of Cmax corresponding to the coefficient of variation of 50% is log. Since it is within log 1.4319 of 0.6984, it has been proven to be biologically equivalent in accordance with Article 17 (4) of the Pharmaceutical Equivalence Test Standards.
* Table: refer to manual
B. Postprandial test
The test drug Betagron extended-release tablets 50 mg (Mirabegron) [Genuone Science Co., Ltd.] and the reference drug Betamiga extended-release tablets 50 mg (Mirabegron) [Korea Astellas Pharmaceuticals Co., Ltd.] were administered orally to healthy adults, one tablet each, on an empty stomach in a 2 The coefficient of variation was 37%. When the comparative evaluation item value (AUCt) is log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference is within log 0.8 to log 1.25, and when the comparative evaluation item value (Cmax) is log-transformed and statistically processed, the mean difference is within log 0.8 to log 1.25, and the 90% confidence interval of the log-transformed mean difference of Cmax, which corresponds to a coefficient of variation of 37%, is log. Since it is within log 1.3129 of 0.7617, it has been proven to be biologically equivalent in accordance with Article 17 (4) of the Pharmaceutical Equivalence Test Standards.
* Table: refer to manual
※ This drug uses the same raw materials as Genuine Science Co., Ltd. Betagron extended-release tablet 50 mg (Mirabegron) and the entire process was manufactured by Genuine Science Co., Ltd. using the same manufacturing method.
10. Other
1) The target organs of toxicity were identified in non-clinical tests, which are consistent with clinical observations. Transient elevations in liver enzymes and hepatocellular changes (necrosis and reduction of glycogen particles) were observed in rats. Increased heart rate has been observed in rats, rabbits, dogs, and monkeys. In vivo genotoxicity and carcinogenicity tests showed no genotoxic or carcinogenic potential.
2) The effect on fertility was not shown at sub-lethal doses (the human equivalent dose is 19 times higher than the MHRD (maximum recommended human dose)). Key observations in the rabbit fetal development study included cardiac malformations (aortic dilatation, cardiac hypertrophy) at systemic exposures 36 times higher than those observed in MHRD. Additionally, lung deformities (absence of parapulmonary lobes) and postimplantation miscarriage were observed in rabbits at a whole-body exposure 14 times higher than during MHRD observation, and reversible effects on ossification (ripple ribs, delayed ossification, ossified sternal iliac bones, and reduction in the number of metatarsals) were reported at a whole-body exposure 22 times higher than during MHRD observation. Observed embryo-fetal toxicity occurred at doses associated with maternal toxicity. The cardiac malformations observed in rabbits appear to be mediated through activation of beta 1 adrenergic receptors.
3) In a pharmacokinetic study conducted with this radioactively labeled drug, the parent compound and/or its metabolites were secreted into rat milk at a concentration 1.7 times higher than the plasma concentration 4 hours after administration.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
90 tablets/box (10 tablets/PTP×9)
7. Period of use
18 months from date of manufacture